- Home
- ALKS vs BPMC Comparison
ALKS vs BPMC Comparison
Compare ALKS & BPMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALKS
- BPMC
- Stock Information
- Founded
- ALKS 1987
- BPMC 2008
- Country
- ALKS Ireland
- BPMC United States
- Employees
- ALKS N/A
- BPMC N/A
- Industry
- ALKS Biotechnology: Pharmaceutical Preparations
- BPMC Biotechnology: Pharmaceutical Preparations
- Sector
- ALKS Health Care
- BPMC Health Care
- Exchange
- ALKS Nasdaq
- BPMC Nasdaq
- Market Cap
- ALKS 4.8B
- BPMC 5.8B
- IPO Year
- ALKS 1991
- BPMC 2015
- Fundamental
- Price
- ALKS $31.29
- BPMC $127.79
- Analyst Decision
- ALKS Buy
- BPMC Buy
- Analyst Count
- ALKS 13
- BPMC 18
- Target Price
- ALKS $38.85
- BPMC $125.06
- AVG Volume (30 Days)
- ALKS 1.6M
- BPMC 2.9M
- Earning Date
- ALKS 07-23-2025
- BPMC 07-31-2025
- Dividend Yield
- ALKS N/A
- BPMC N/A
- EPS Growth
- ALKS N/A
- BPMC N/A
- EPS
- ALKS 2.09
- BPMC N/A
- Revenue
- ALKS $1,513,770,000.00
- BPMC $562,121,000.00
- Revenue This Year
- ALKS N/A
- BPMC $44.49
- Revenue Next Year
- ALKS $4.11
- BPMC $33.04
- P/E Ratio
- ALKS $14.95
- BPMC N/A
- Revenue Growth
- ALKS N/A
- BPMC 99.19
- 52 Week Low
- ALKS $22.90
- BPMC $73.04
- 52 Week High
- ALKS $36.45
- BPMC $128.15
- Technical
- Relative Strength Index (RSI)
- ALKS 57.40
- BPMC 76.54
- Support Level
- ALKS $29.70
- BPMC $94.38
- Resistance Level
- ALKS $31.76
- BPMC $102.52
- Average True Range (ATR)
- ALKS 0.75
- BPMC 3.48
- MACD
- ALKS 0.01
- BPMC 1.32
- Stochastic Oscillator
- ALKS 81.64
- BPMC 98.93
About ALKS Alkermes plc
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
About BPMC Blueprint Medicines Corporation
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.